Eli Lilly | LLY - Net Income

Stock Price
1,042.15
Daily Change
-16.41 -1.55%
Monthly
-1.94%
Yearly
15.56%
Q1 Forecast
978.22

Eli Lilly reported $6.64B in Net Income for its fiscal quarter ending in December of 2025.





Net Income Change Date
AbbVie USD 1.82B 1.63B Dec/2025
Abbott USD 1.78B 132M Dec/2025
ALKERMES USD 82.76M 4.34M Sep/2025
Amgen USD 1.33B 1.88B Dec/2025
AstraZeneca USD 2.33B 207M Dec/2025
Baxter International USD -1.13B 1.08B Dec/2025
Biogen USD 466.5M 168.3M Sep/2025
Bristol-Myers Squibb USD 1.09B 1.11B Dec/2025
Coherus Biosciences USD -56.57M 5.87M Mar/2025
Drreddys Laboratories INR 12.1B 2.08B Dec/2025
Eli Lilly USD 6.64B 1.05B Dec/2025
Gilead Sciences USD 2.18B 869M Dec/2025
GlaxoSmithKline GBP 636M 1.38B Dec/2025
Glaxosmithkline GBP 2.71B 1.27B Sep/2025
J&J USD 5.12B 36M Dec/2025
Medtronic USD 1.14B 231M Dec/2025
Merck USD 2.96B 2.82B Dec/2025
Neurocrine Biosciences USD 209.5M 102M Sep/2025
Novartis USD 3.93B 96M Sep/2025
Novartis USD 3.93B 113M Sep/2025
Novo Nordisk DKK 26.89B 388M Dec/2025
Perrigo USD 7.5M 15.9M Sep/2025
Pfizer USD -1.65B 5.19B Dec/2025
Phibro Animal Health USD 3.18M 3.79M Dec/2024
Prestige Brands USD 46.7M 22.44M Dec/2025
Regeneron Pharmaceuticals USD 844.6M 615.4M Dec/2025
Roche Holding CHF 5.47B 1.76B Dec/2025
Sanofi EUR -801M 3.6B Dec/2025
Sanofi EUR -801M 3.6B Dec/2025
United Therapeutics USD 338.7M 29.2M Sep/2025
Zoetis USD 603M 118M Dec/2025